Relapsed medulloblastoma (MB) is a highly lethal disease, requiring for new effective treatment strategies. Intrathecal (IT) therapy both for de novo or relapsed brain tumors with meningeal metastasis is rarely used in first line and relapse protocols.We report on three cases of children with relapsed MB treated with IT liposomal cytarabine administered after mild sedation every 15 days.The treatment was well-tolerated in all patients, achieving a prolonged progression-free survival (4-11 months) with a good quality of life.This experience suggests the need for a phase II trial in brain embryonal tumors with leptomeningeal metastasis to better evaluate the efficacy of IT liposomal cytarabine.
Intrathecal liposomal cytarabine and leptomeningeal medulloblastoma relapse: a valuable therapeutic option / Mastronuzzi, Angela; F. D., Bufalo; A., Iacono; D. E., Secco; A., Serra; G. S., Colafati; M. A., De; T., Corsetti. - In: ANTICANCER RESEARCH. - ISSN 0250-7005. - 33:(2013), pp. 3515-3518.
Intrathecal liposomal cytarabine and leptomeningeal medulloblastoma relapse: a valuable therapeutic option.
MASTRONUZZI, ANGELA;
2013
Abstract
Relapsed medulloblastoma (MB) is a highly lethal disease, requiring for new effective treatment strategies. Intrathecal (IT) therapy both for de novo or relapsed brain tumors with meningeal metastasis is rarely used in first line and relapse protocols.We report on three cases of children with relapsed MB treated with IT liposomal cytarabine administered after mild sedation every 15 days.The treatment was well-tolerated in all patients, achieving a prolonged progression-free survival (4-11 months) with a good quality of life.This experience suggests the need for a phase II trial in brain embryonal tumors with leptomeningeal metastasis to better evaluate the efficacy of IT liposomal cytarabine.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
